Zacks Investment Research downgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a strong-buy rating to a hold rating in a report issued on Tuesday morning.
According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “
Other equities analysts have also recently issued reports about the stock. Canaccord Genuity restated a buy rating and issued a $15.00 price target on shares of Akari Therapeutics in a research report on Friday, September 22nd. William Blair upgraded shares of Akari Therapeutics from a market perform rating to an outperform rating in a research report on Friday, September 22nd. Finally, ValuEngine upgraded shares of Akari Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $7.50.
Akari Therapeutics (NASDAQ:AKTX) last announced its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.00) by $0.91. equities research analysts expect that Akari Therapeutics will post -2 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Akari Therapeutics stock. VHCP Management II LLC grew its position in Akari Therapeutics PLC (NASDAQ:AKTX) by 15.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 426,297 shares of the biopharmaceutical company’s stock after purchasing an additional 56,807 shares during the quarter. Akari Therapeutics makes up about 0.8% of VHCP Management II LLC’s portfolio, making the stock its 13th largest position. VHCP Management II LLC owned 3.62% of Akari Therapeutics worth $1,965,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 20.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://weekherald.com/2018/01/20/akari-therapeutics-aktx-rating-lowered-to-hold-at-zacks-investment-research.html.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.